Skip to main content

Table 6 Comparison of characteristics between RA patients who never achieved remission and those who achieved and maintained remission (case–control study, nested within the cohort)

From: Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity

Characteristic

RA patients who achieved and maintained remission

RA patients who never achieved sustained remission

P value

( n= 46)

( n= 14)

Socio-demographic

   

Female gender

40 (87%)

14 (100)

0.32

Age (years)

38.2 ± 10.5

38.7 ± 12.5

0.88

Years of formal education

10.5 ± 8.8

10 ± 7.7

0.43

Current smokers

5 (10.9)

0 (0)

0.33

Females with menopause (142 female)

2 (5)

1 (7)

1

Baseline BMI (kg/m2)

25.1 (22 to 27.5)

27.8 (23.1 to 30.4)

0.05

Disease characteristics

   

Disease duration (months)

5.8 (4.1 to 7.7)

3.3 (1.6 to 6)

0.03

Patients with ACCP

38 (82.6)

13 (92.9)

0.67

Baseline DAS28

6 (4.6 to 6.8)

7.3 (6.5 to 7.8)

0.002

Baseline ESR (mm/hour)

24.5 (14.3 to 37)

43 (28.3 to 59.5)

0.012

Baseline CRP (mg/dl)

1 (0.3 to 3.4)

2.4 (1.4 to 6.1)

0.05

Baseline HAQ

1.4 (0.6 to 2)

2.3 (1.6 to 3)

0.008

Patients with erosions at baseline

5 (11)

0 (0)

0.33

Follow-up (months)

88 (58.5 to 108)

87 (57 to 108)

0.96

Incidental MetS

19 (41.3)

11 (78.6)

0.03

Comorbid conditions

   

Patients with diabetes

1 (2.2)

0 (0)

1

Patients with hypertension

1 (2.2)

0 (0)

1

Patients with BMI ≥30 kg/m2

4 (8.7)

6 (42.9)

0.007

Treatment up to sustained remission a

   

Number of DMARDs/patient

2 (2 to 2.5)

2.5 (2 to 2.75)

0.08

Patients with corticosteroids

30 (65.2)

9 (64.3)

1

  1. Data presented as n (%), mean ± standard deviation or median (range). ACCP, antibodies to cyclic citrullinated peptides; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score evaluated in 28 joints; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; RA, rheumatoid arthritis. aIn those who never achieved remission, complete follow-up was considered.